China, Oct. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical and pathological characteristics and response to targeted therapy in ALK-positive lung squamous cell carcinoma: a multicentre retrospective real-world study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600134274
Registration Time: 2026/10/13
Type: Observational study
Primary Sponsor: Shandong Provincial Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=303819
Published by HT Digital Content Services with permission from Health Daily Digest....